Israel Englander’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $564M | Sell |
40,000
-400
| -1% | -$75.2K | 0.2% | 69 |
|
|
2026
Q1 | $588M | Sell |
40,400
-25,650
| -39% | -$4.95M | 0.24% | 56 |
|
|
2025
Q4 | $12.1M | Sell |
66,050
-123,650
| -65% | -$21.7M | 0.01% | 2058 |
|
|
2025
Q3 | $29.1M | Buy |
189,700
+101,800
| +116% | +$15.4M | 0.01% | 1292 |
|
|
2025
Q2 | $12.3M | Sell |
87,900
-16,750
| -16% | -$2.35M | 0.01% | 2048 |
|
|
2025
Q1 | $15.4M | Buy |
104,650
+52,700
| +101% | +$7.62M | 0.01% | 1776 |
|
|
2024
Q4 | $6.81M | Sell |
51,950
-34,500
| -40% | -$4.83M | ﹤0.01% | 2525 |
|
|
2024
Q3 | $13.5M | Sell |
86,450
-321,600
| -79% | -$51.9M | 0.01% | 1922 |
|
|
2024
Q2 | $63.6M | Buy |
408,050
+304,800
| +295% | +$45.9M | 0.03% | 654 |
|
|
2024
Q1 | $14M | Buy |
103,250
+53,100
| +106% | +$7.03M | 0.01% | 1870 |
|
|
2023
Q4 | $6.76M | Sell |
50,150
-104,000
| -67% | -$13.5M | ﹤0.01% | 2527 |
|
|
2023
Q3 | $20.9M | Sell |
154,150
-265,450
| -63% | -$36.3M | 0.01% | 1404 |
|
|
2023
Q2 | $60.1M | Buy |
419,600
+404,000
| +2,590% | +$59.4M | 0.03% | 618 |
|
|
2023
Q1 | $2.17M | Sell |
15,600
-71,450
| -82% | -$9.61M | ﹤0.01% | 3367 |
|
|
2022
Q4 | $11.8M | Buy |
87,050
+40,900
| +89% | +$5.13M | 0.01% | 1942 |
|
|
2022
Q3 | $5.06M | Sell |
46,150
-4,450
| -9% | -$565K | ﹤0.01% | 2878 |
|
|
2022
Q2 | $6.69M | Sell |
50,600
-152,200
| -75% | -$20M | ﹤0.01% | 2493 |
|
|
2022
Q1 | $26.9M | Buy |
+202,800
| New | +$24.3M | 0.01% | 1106 |
|
|
2021
Q4 | – | Sell |
-257,700
| Closed | -$13.8M | – | 6776 |
|
|
2021
Q3 | $13.8M | Buy |
257,700
+206,550
| +404% | +$24M | 0.01% | 1667 |
|
|
2021
Q2 | $6.13M | Hold |
51,150
| – | – | ﹤0.01% | 2486 |
|
|
2021
Q1 | $5.09M | Buy |
+51,150
| New | +$5.14M | ﹤0.01% | 2549 |
|
|
2020
Q4 | – | Sell |
-8,750
| Closed | -$960 | – | 5188 |
|
|
2020
Q3 | $960 | Buy |
+8,750
| New | +$973K | ﹤0.01% | 3170 |
|
|
2019
Q2 | – | Sell |
-100,000
| Closed | -$8.09M | – | 4044 |
|
|
2019
Q1 | $8.09M | Buy |
+100,000
| New | +$7.88M | 0.01% | 1417 |
|
|
2017
Q3 | – | Sell |
-75,000
| Closed | -$5.11M | – | 3498 |
|
|
2017
Q2 | $5.11M | Sell |
75,000
-5,000
| -6% | -$327K | 0.01% | 1492 |
|
|
2017
Q1 | $4.98M | Buy |
80,000
+75,000
| +1,500% | +$4.37M | 0.01% | 1458 |
|
|
2016
Q4 | $273K | Buy |
+5,000
| New | +$284K | ﹤0.01% | 2945 |
|
|
2015
Q2 | – | Sell |
-4,100
| Closed | -$281K | – | 3311 |
|
|
2015
Q1 | $281K | Buy |
+4,100
| New | +$285K | ﹤0.01% | 3083 |
|
|
2014
Q3 | – | Sell |
-5,100
| Closed | -$379K | – | 3680 |
|
|
2014
Q2 | $379K | Buy |
+5,100
| New | +$369K | ﹤0.01% | 2747 |
|
|
2013
Q4 | – | Sell |
-63,900
| Closed | -$3.32M | – | 3441 |
|
|
2013
Q3 | $3.32M | Buy |
+63,900
| New | +$3.21M | 0.01% | 1360 |
|
Other funds holding AZN
EP
IA
Israel Englander's AZN Position: Q2 2026 in Review
Israel Englander reduced its AstraZeneca (AZN) stake by 55% in Q2 2026, selling an estimated $136M and leaving 581,913 shares worth $110M. The position accounts for 0.04% of the portfolio, ranked #468.
Israel Englander first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. The position peaked at $257M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Israel Englander held 581,913 shares of AstraZeneca worth $110M as of Q2 2026.
- Israel Englander sold 720,732 AstraZeneca shares in Q2 2026, an estimated $136M.
- AstraZeneca made up 0.04% of Israel Englander's portfolio in Q2 2026, its #468 holding.
- Israel Englander first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
- Israel Englander's AstraZeneca position peaked at $257M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.